OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Pazopanib"

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates. At the annual meeting ...


A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer.At the annual meeting of the American Society of Clinical O ...


Pazopanib ( Votrient ) and Sunitinib ( Sutent ) provided a progression-free survival benefit, as compared with placebo or Interferon, in previous phase 3 studies involving patients with metastatic ren ...


Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug ...


Neuroendocrine tumors ( NETs ) are a heterogeneous class of neoplasms with increasing incidence worldwide. Tumor behavior and patient survival largely depend upon a number of different factors such ...


Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...